混合合成/生物补片首次人体用于腹壁疝修补的多中心试验
这项前瞻性多中心上市后临床试验首次在人体中评估了新型合成/生物混合补片(Zenapro®)用于腹壁/切口疝修补。共纳入63例VHWG 1-3级、清洁或清洁-污染切口的患者,补片置于腹腔内或腹膜前/肌后位置。12个月随访时复发率为6.8%(95%CI 2.2-16.6%),手术部位事件发生率为39%,以浆液肿最常见(23.7%),但仅少数需干预。结论认为该混合补片在VHWG 1-2级清洁切口患者中安全有效,短期结果可接受。
要点
- 混合补片用于腹壁疝修补12个月复发率为6.8%(95%CI 2.2-16.6%)
- 手术部位事件发生率39%,浆液肿最常见(23.7%),仅8.5%需干预
- 结论适用于VHWG 1-2级、清洁切口的患者
核心结论
- Zenapro®混合补片在VHWG 1-2级、清洁切口的腹壁/切口疝修补患者中安全有效,随访至12个月。
- 短期结果和复发率可接受,该混合补片为腹壁/切口疝修补提供了新的加强选择。
研究设计与样本
- 前瞻性、多中心上市后临床试验,连续纳入接受择期腹壁/切口疝修补并使用混合补片的成人患者。
- 共63例患者,补片置于腹腔内或肌后/腹膜前位置,按VHWG 1-3级分类且为清洁或清洁-污染切口。
主要发现
- 患者女性占54.0%,平均年龄54.8±10.9岁,平均BMI 34.5±7.8 kg/m2,VHWG 2级占87.3%。
- 缺损多位于中线(92.1%),平均面积106±155 cm2;清洁切口占92.1%,腹腔镜手术占60.3%。
- 原发性筋膜关闭率82.5%,28.2%需要组织分离;补片多置于腹腔内(69.8%)。
- 12个月随访时39%的患者发生手术部位事件,切口疝修补后更常见;浆液肿最常见(23.7%),仅8.5%需干预。
- 需干预的其他手术部位事件包括血肿(1.7%)、伤口裂开(1.7%)和手术部位感染(3.4%);12个月复发率为6.8%(95%CI 2.2-16.6%)。
临床怎么用
- 对于VHWG 1-2级、清洁切口的腹壁/切口疝患者,可考虑使用该混合补片进行加强修补。
- 术后应关注浆液肿等手术部位事件,但多数无需干预。
局限性
- 样本量较小(63例),随访时间仅12个月。
- 未与合成或生物补片单用进行对照,结论需更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesh options for reinforcement of ventral/incisional hernia (VIH) repair include synthetic or biologic materials. While each material has known advantages and disadvantages, little is understood about outcomes when these materials are used in combination. This multicenter study reports on the first human use of a novel synthetic/biologic hybrid mesh (Zenapro® Hybrid Hernia Repair Device) for VIH repair. METHODS: This prospective, multicenter post-market clinical trial enrolled consecutive adults who underwent elective VIH repair with hybrid mesh placed in the intraperitoneal or retromuscular/preperitoneal position. Patients were classified as Ventral Hernia Working Group (VHWG) grades 1-3 and had clean or clean-contaminated wounds. Outcomes of ventral and incisional hernia were compared using appropriate parametric tests. RESULTS: In all, 63 patients underwent VIH repair with hybrid mesh. Most were females (54.0%), had a mean age of 54.8 ± 10.9 years and mean body mass index of 34.5 ± 7.8 kg/m2, and classified as VHWG grade 2 (87.3%). Most defects were midline (92.1%) with a mean area of 106 ± 155 cm2. Cases were commonly classified as clean (92.1%) and were performed laparoscopically (60.3%). Primary fascial closure was achieved in 82.5% with 28.2% requiring component separation. Mesh location was frequently intraperitoneal (69.8%). Overall, 39% of patients available for follow-up at 12 months suffered surgical site events, which were generally more frequent after incisional hernia repair. Of these, seroma (23.7%) was most common, but few (8.5%) required procedural intervention. Other surgical site events that required procedural intervention included hematoma (1.7%), wound dehiscence (1.7%), and surgical site infection (3.4%). Recurrence rate was 6.8% (95% CI 2.2-16.6%) at 12-months postoperatively. CONCLUSION: Zenapro® Hybrid Hernia Repair Device is safe and effective in VHWG grade 1-2 patients with clean wounds out to 12 months. Short-term outcomes and recurrence rate are acceptable. This hybrid mesh represents a novel option for reinforcement during VIH repair.
引用
- Bittner JG, El-Hayek K, Strong AT, et al. First human use of hybrid synthetic/biologic mesh in ventral hernia repair: a multicenter trial. Surg Endosc. 2017. PMID: 28726148. doi:10.1007/s00464-017-5715-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。